Merck & Co. MRK
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Merck & Co. (MRK) Business Model and Operations Summary
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Key Insights
Merck & Co. (MRK) Core Market Data and Business Metrics
Latest Closing Price
$87.12Market Cap
$220.31 BillionPrice-Earnings Ratio
12.93Total Outstanding Shares
2.53 Billion SharesTotal Employees
75,000Dividend
$0.81 Per Share QuarterlyIPO Date
April 20, 1949SIC Description
Pharmaceutical PreparationsPrimary Exchange
New York Stock ExchangeHeadquarters
2000 Galloping Hill Road, Kenilworth, NJ, 07033
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $6.70 Billion |
| Exchange Gains/Losses | $-293 Million |
| Net Cash Flow From Investing Activities | $-7.73 Billion |
| Net Cash Flow | $6.41 Billion |
| Net Cash Flow From Operating Activities | $21.47 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-7.73 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Costs And Expenses | $44.23 Billion |
| Income Tax Expense/Benefit, Deferred | $-1.25 Billion |
| Operating Expenses | $29.04 Billion |
| Selling, General, and Administrative Expenses | $10.82 Billion |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Research and Development | $17.94 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $17.33 Billion |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss Attributable To Parent | $216 Million |
| Other Comprehensive Income/Loss | $216 Million |
| Comprehensive Income/Loss | $17.33 Billion |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Current Liabilities | $28.42 Billion |
| Other Current Assets | $32.67 Billion |
| Other Non-current Assets | $38.17 Billion |
| Noncurrent Liabilities | $42.31 Billion |
| Fixed Assets | $23.78 Billion |
| Liabilities And Equity | $117.11 Billion |
Historical Dividends
Current dividend: $0.81 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Jan 28, 2025 | Apr 7, 2025 | Mar 17, 2025 | $0.81 | Quarterly |
| Nov 19, 2024 | Jan 8, 2025 | Dec 16, 2024 | $0.81 | Quarterly |
| Jul 23, 2024 | Oct 7, 2024 | Sep 16, 2024 | $0.77 | Quarterly |
| May 28, 2024 | Jul 8, 2024 | Jun 17, 2024 | $0.77 | Quarterly |
| Jan 23, 2024 | Apr 5, 2024 | Mar 15, 2024 | $0.77 | Quarterly |
| Nov 28, 2023 | Jan 8, 2024 | Dec 15, 2023 | $0.77 | Quarterly |